Pulmonary Arterial Hypertension (PAH) Clinical Trial Pipeline Analysis: 20+ Key Companies Shaping the Future of PAH Therapeutics | DelveInsight

DelveInsight's Pulmonary Arterial Hypertension (PAH) Pipeline Insight 2026 report provides comprehensive global coverage of available, marketed, and pipeline PAH therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the PAH pipeline domain.

Key takeaways from the PAH Clinical Trial Landscape Report
• DelveInsight's PAH pipeline report depicts a robust space with 20+ active players working to develop multiple pipeline therapies for PAH treatment.
• Key PAH companies such as United Therapeutics, Pfizer, Respira Therapeutics, Gossamer Bio, Liquidia Technologies, Pharmosa Biopharm, Merck Sharp & Dohme LLC, and others.
• Promising PAH pipeline therapies in various stages of development include Ralinepag, RT234 (vardenafil inhalation powder), Seralutinib (GB002), YUTREPIA, L606, and others.

Request a sample and discover the recent advances in PAH treatment drugs at https://www.delveinsight.com/sample-request/pulmonary-arterial-hypertension-pipeline-insight?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

What is Pulmonary Arterial Hypertension (PAH)?
Pulmonary Hypertension is defined as a mean pulmonary artery pressure of more than 20 mm Hg measured by right heart catheterization. It is often characterized by a progressive and sustained increase in pulmonary vascular resistance (PVR) that eventually leads to right ventricular failure. It can be a life-threatening condition if untreated. The World Health Organization (WHO) has divided Pulmonary Hypertension into five groups based on similarities in pathophysiology, clinical presentation, and therapeutic options. Pulmonary Arterial Hypertension (PAH) belongs to WHO Group 1 and includes idiopathic PAH, heritable PAH, drug- and toxin-induced PAH, and PAH associated with other diseases and disorders.

Emerging PAH Drug Profiles

Ralinepag: United Therapeutics
Ralinepag is a novel, oral, selective, and potent prostacyclin receptor agonist being developed by United Therapeutics for the treatment of PAH. In vitro studies indicate that ralinepag has high binding affinity and selectivity at the human prostacyclin receptor. In Phase II studies, ralinepag demonstrated a potential for a once-a-day dosing profile and enhanced affinity compared to selexipag. United Therapeutics is currently assessing ralinepag in a Phase III ADVANCE OUTCOMES registrational study with topline data projected for release in H1 2026.

RT234: Respira Therapeutics
Respira's lead drug-device product candidate, RT234-PAH, is a first-in-class inhaled therapy intended for as-needed use to improve exercise tolerance and provide acute relief from breathlessness and fatigue, the most commonly reported symptoms in PAH patients. Respira has received FDA Orphan Drug designation for RT234 and is currently evaluating the therapy in Phase II clinical testing for PAH.

Learn more about the novel and emerging PAH pipeline therapies at: https://www.delveinsight.com/sample-request/pulmonary-arterial-hypertension-pipeline-insight?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

Recent Developments in the PAH Clinical Trial Landscape
• In December 2025, Merck received a positive EU CHMP opinion for the expanded use of WINREVAIR (sotatercept) in adults with PAH (WHO Group 1).
• In June 2025, United Therapeutics announced completion of enrollment in the Phase III ADVANCE OUTCOMES trial of extended-release ralinepag for PAH.
• In May 2025, Respira Therapeutics announced late-breaking presentation of RT234 Phase IIb PAH clinical trial results at the American Thoracic Society (ATS) 2025 International conference.
• In February 2025, United Therapeutics presented clinical data at the Pulmonary Vascular Research Institute Annual Congress highlighting real-world dosing data of TYVASO DPI in PAH.
• In September 2025, Respira Therapeutics entered into an agreement with Gossamer Bio, under which Gossamer was granted an option to acquire the company.

Scope of the PAH Pipeline Report
• Coverage: Global
• Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
• Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Therapeutics Assessment By Route of Administration: Oral, Intravenous, Parenteral, Subcutaneous, Inhalation
• Therapeutics Assessment By Molecule Type: Small molecule, Recombinant fusion proteins, Monoclonal antibody, Prostacyclin receptor agonist, Gene Therapy
• Key PAH Companies: United Therapeutics, Pfizer, Respira Therapeutics, Gossamer Bio, Liquidia Technologies, Pharmosa Biopharm, Merck Sharp & Dohme LLC, and others
• Key PAH Pipeline Therapies: Ralinepag, RT234, Seralutinib (GB002), YUTREPIA, L606, and others

Dive deep into rich insights for new drugs for PAH treatment, visit https://www.delveinsight.com/sample-request/pulmonary-arterial-hypertension-pipeline-insight?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

Table of Contents
1. PAH Pipeline Report Introduction
2. PAH Pipeline Report Executive Summary
3. PAH Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. PAH Pipeline Therapeutics
6. PAH Pipeline: Late Stage Products (Pre-registration)
7. PAH Pipeline: Late Stage Products (Phase III)
8. PAH Pipeline: Mid Stage Products (Phase II)
9. PAH Pipeline: Early Stage Products (Phase I)
10. PAH Pipeline Therapeutics Assessment
11. Inactive Products in the PAH Pipeline
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Key Companies
14. Key Products in the PAH Pipeline
15. Unmet Needs
16. Market Drivers and Barriers
17. Future Perspectives and Conclusion
18. Analyst Views
19. Appendix

For further information on the PAH pipeline therapeutics, reach out at https://www.delveinsight.com/sample-request/pulmonary-arterial-hypertension-pipeline-insight?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

Company Name: DelveInsight Business Research LLP
Contact Person: Kirti Sharma
Email: info@delveinsight.com
Phone: +14699457679
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through their subscription-based platform PharmDelve.

This release was published on openPR.